ProShares Trust - ProShares UltraShort S&P500 -2x Shares
SDS
Market Cap$26.94M
Close$
$-6.98
138.7% downside
Current Fair Value
138.7% downsideOvervalued by 138.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $26.94 Million |
|---|---|
| Enterprise Value | $33.20 Million |
| Dividend Yield | $1.44177 (7.81447154471545%) |
| Earnings per Share | $0 |
| Beta | -1.96 |
| Outstanding Shares | 1,893,127 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.94 |
|---|---|
| PEG | 6.31 |
| Price to Sales | 3.01 |
| Price to Book Ratio | 1.39 |
| Enterprise Value to Revenue | 2.65 |
| Enterprise Value to EBIT | -3.9 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...